Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 15:15:1458621.
doi: 10.3389/fphar.2024.1458621. eCollection 2024.

Plant medicine metabolite Yulinzhu treating neurological disorder causing polycystic ovary syndrome: a systematic review and a meta-analysis

Beibei Jiao #  1 , Ruilin Chen #  2 , Si Chen  1 , Jian Zhang  1 , Peijuan Wang  1 , Huaijun Zhou  2 , Weibo Zhao  3
Affiliations

Plant medicine metabolite Yulinzhu treating neurological disorder causing polycystic ovary syndrome: a systematic review and a meta-analysis

Beibei Jiao et al. Front Pharmacol. .

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that affects women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Emerging evidence indicates that neurological disorders play a significant role in the etiology of PCOS, highlighting the complex interplay between the central nervous system (CNS) and ovarian function. Yulinzhu, a traditional Chinese medicine (TCM) formulation, has been traditionally used to regulate menstrual cycles and improve fertility. This study aims to investigate the efficacy and mechanisms of Yulinzhu in treating PCOS induced by neurological disorders.

Methods: An extensive literature search was performed across electronic databases such as PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI), covering publications up to 1 June 2024. The review included randomized controlled trials (RCTs) that compared Yulin Zhu with placebo, standard care, or other active treatments in patients with PCOS. Two reviewers independently carried out data extraction and quality assessment. Meta-analyses were conducted using both fixed and random-effects models, with heterogeneity evaluated using the I2 statistic.

Results: We screened 891 records and included 6 studi es in the meta-analysis. The meta-analysis revealed that Yulinzhu about effective rate [RR = 1.19, 95% CI (1.10, 1.29), p < 0.0001], pregnancy rate [RR = 2.80, 95% CI (1.65, 4.76), p < 0.0001] and ovulation rate [RR = 1.33, 95% CI (1.10, 1.62), p = 0.04]. Meta-analysis shows the results of follicle estrogen [WMD = 0.69, 95% CI (-0.39, 1.78), p = 0.21], luteinizing hormone [WMD = -2.27, 95% CI (-3.86, -0.67), p = 0.005], testosterone [WMD = -0.44, 95% CI (-0.64, -0.25), p < 0.0001], estradiol [WMD = 16.20, 95% CI (2.74, 29.67), p < 0.0001].

Conclusion: This study demonstrates that plant medicine compund Yulinzhu may effectively treats PCOS including hormonal regulation, anti-inflammatory actions, and neuroprotection. We expect further research with larger, well-designed clinical trials to substantiate our conclusions.

Keywords: Yulinzhu; hormonal regulation; neurological disorders; neuroprotection; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Literature retrieval process.
FIGURE 2
FIGURE 2
Risk of bias (A) Risk of bias graph 3
FIGURE 3
FIGURE 3
Effective rate of Yulinzhu treatment (A) forest plot of effective rate (B) funnel plot of effective rate (C) Sensitivity analysis.
FIGURE 4
FIGURE 4
Pregnancy rate of Yulinzhu treatment (A) forest plot of pregnancy rate (B) funnel plot of pregnancy rate (C) Sensitivity analysis.
FIGURE 5
FIGURE 5
Ovulation rate of Yulinzhu treatment (A) forest plot of ovulation rate (B) funnel plot of ovulation rate (C) Sensitivity analysis.
FIGURE 6
FIGURE 6
F Follicle-Stimulating Hormone of Yulinzhu treatment (A) forest plot of follicle-Stimulating Hormone (B) funnel plot of follicle-Stimulating Hormone (C) Sensitivity analysis.
FIGURE 7
FIGURE 7
Luteinizing hormone of Yulinzhu treatment (A) forest plot of luteinizing hormone (B) funnel plot of luteinizing hormone (C) Sensitivity analysis.
FIGURE 8
FIGURE 8
Testosterone of Yulinzhu treatment (A) forest plot of testosterone (B) funnel plot of testosterone (C) Sensitivity analysis.
FIGURE 9
FIGURE 9
Estradiol of Yulinzhu treatment (A) forest plot of estradiol (B) funnel plot of estradiol (C) Sensitivity analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abruzzese G. A., Velazquez M. E., Cerrone G. E., Motta A. B. (2023). Polycystic ovary syndrome in Latin American populations: what is known and what remains unresolved. J. Steroid Biochem. Mol. Biol. 225, 106195. 10.1016/j.jsbmb.2022.106195 - DOI - PubMed
    1. Andrade V. H., Mata A. M., Borges R. S., Costa-Silva D. R., Martins L. M., Ferreira P. M., et al. (1992)2016). Current aspects of polycystic ovary syndrome: a literature review. Rev. Assoc. Med. Bras. 62 (9), 867–871. 10.1590/1806-9282.62.09.867 - DOI - PubMed
    1. Chang S., Dunaif A. (2021). Diagnosis of polycystic ovary syndrome: which criteria to use and when? Endocrinol. Metab. Clin. North Am. 50 (1), 11–23. 10.1016/j.ecl.2020.10.002 - DOI - PMC - PubMed
    1. Ding H., Zhang J., Zhang F., Zhang S., Chen X., Liang W., et al. (2021). Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Front. Endocrinol. (Lausanne) 12, 741764. 10.3389/fendo.2021.741764 - DOI - PMC - PubMed
    1. Fan H., Ren Q., Sheng Z., Deng G., Li L. (2023). The role of the thyroid in polycystic ovary syndrome. Front. Endocrinol. (Lausanne) 14, 1242050. 10.3389/fendo.2023.1242050 - DOI - PMC - PubMed

Publication types